Ensign Energy Services Inc.

Good afternoon, ladies and gentlemen, and welcome to the Enzyme Energy Services Incorporated fourth quarter 2025 results conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded today, Friday, March 6, 2026. I would now like to turn the conference over to Mike Gray, Chief Financial Officer, please go ahead, sir. Thank you.

Good morning, and welcome to Enzyme Energy Services' fourth quarter conference call and webcast. On our call today, Bob Geddes, President and COO, and myself, Mike Gray, Chief Financial Officer, will review Enzyme's fourth quarter highlights and financial results, followed by operational update and outlook. We'll open the call for questions after that. Our discussions today may include forward-looking statements based upon current expectations that involve several business risks and uncertainties. The factors that could cause results to differ materially include, but are not limited to, political, economic, and marketing conditions, crude oil and natural gas prices, foreign currency fluctuations, weather conditions, the company's defense of lawsuits, the ability of oil and gas companies to pay accounts receivable balances, or other unforeseen conditions which could impact the demand for services supplied by the company. Additionally, our discussion today may refer to non-GAAP financial measures such as adjusted EBITDA, Please see our fourth quarter earnings release and CDR Plus filing for more information on forward-looking statements and the company's use of non-GAAP financial measures. On that, I will pass the call back to Bob.

Thanks, Mike. Good morning or afternoon, everyone, wherever you're at. Some introductory comments. The fourth quarter of 2025 provides a great deal to discuss, both in terms of reflecting on the full year's performance and looking ahead to the opportunities and challenges that lie in front of us. The Enzyme team completed the 2025 year with results that exceeded analyst estimates, both for the quarter and the full year. And most importantly, we were able to clip off an additional $80 million of debt in 2025. The Canadian business unit led the way with year-over-year EBITDA gains, while the US battled great headwinds. In 2025, the team was successful in getting operators to fund roughly half of the $48 million in upgrades executed in 2025. These regs are all tied up now in long-term contracts. The team ended the year expanding our forward long-time contract book to $1.2 billion of forward contract coverage, with 60% of the fleet contracted forward. Our international business unit, which operates in Venezuela, Argentina, Australia, Oman, Bahrain, and Kuwait, had a share of ups and downs, which I will expand on later. For deeper diving in the fourth quarter and full year 25, I'll turn it over back to Mike.